

## RNA Targeting Small Molecules Therapeutics Market Segments, Driver, Restraints, And Trends

The Business Research Company's RNA Targeting Small Molecules Therapeutics Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

LONDON, GREATER LONDON, UK, July 2, 2024 /EINPresswire.com/ -- The RNA targeting small molecule therapeutics market has witnessed exponential growth, projected to increase from \$1.06 billion in 2023 to \$1.45 billion in



2024, at a compound annual growth rate (CAGR) of 37.0%. This growth in recent years can be attributed to advancements in drug discovery and development, rising prevalence of RNA-related diseases, substantial government and private funding, increasing interest from the pharmaceutical industry, and successful RNA therapeutics case studies.



You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs"
The Business Research
Company

Rising Demand for Precision Medicine Drives Market Growth

The exponential growth of the RNA targeting small molecule therapeutics market to \$5.09 billion by 2028, at a CAGR of 36.9%, is fueled by the expanding application of precision medicine and personalized therapies. Additionally, the identification of RNA biomarkers,

widening RNA target spectrum, and growing investments contribute significantly to market expansion. The market is particularly gaining momentum in rare disease applications.

Explore the global RNA targeting small molecule therapeutics market with a detailed sample report: <a href="https://www.thebusinessresearchcompany.com/sample-request?id=12253&type=smp">https://www.thebusinessresearchcompany.com/sample-request?id=12253&type=smp</a>

Key Players and Market Trends

Major players such as F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., and AstraZeneca PLC are focusing on developing innovative RNA-targeting small molecule therapies. Trends in the market

include advancements in screening technologies, dominance of antisense oligonucleotides, emergence of small molecule RNA binders, increased application of RNA therapeutics in neurological disorders, and the integration of gene editing technologies like CRISPR-Cas9.

## Segments

- Offering: mRNA Translation Modulators, RNA Splicing Modification, Direct RNA Targeting, Other Offerings
- Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications
- Application: Drug Discovery, Oncology Research, Disease Identification
- End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Geographical Insights: North America Leading the Market

North America dominated the RNA targeting small molecule therapeutics market in 2023 and is expected to continue leading due to advanced healthcare infrastructure, significant investments in research and development, and a high prevalence of RNA-related diseases.

Order your report now for swift delivery

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

RNA Targeting Small Molecules Therapeutics Global Market Report 2024 from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The RNA Targeting Small Molecules Therapeutics Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on RNA targeting small molecules therapeutics market size, RNA targeting small molecules therapeutics market drivers and trends, RNA targeting small molecules therapeutics market major players, competitors' revenues, market positioning, and market growth across geographies. The RNA targeting small molecules therapeutics market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company: Cranes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cranes-global-market-report

Overhead Cranes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/overhead-cranes-global-market-report

Rubber Tired Gantry Crane Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/rubber-tired-gantry-crane-global-market-report

## **About The Business Research Company**

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

**Contact Information** 

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/724506293

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.